Meta Information
ID:noopept
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/class/cholinergic-agonists
Target name:
Cholinergic Agents (e.g., Choline, Alpha-GPC, Acetylcholinesterase Inhibitors)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Noopept modulates cholinergic neurotransmission and is often co-administered with choline precursors (alpha-GPC, CDP-choline) to support acetylcholine synthesis. Cholinergic agents can enhance Noopept's cognitive effects. However, excessive cholinergic stimulation may cause cholinergic adverse effects (headache, nausea, increased salivation, gastrointestinal distress).
Actionable advice:
Combining Noopept with choline sources is generally well-tolerated and may enhance cognitive benefits. Monitor for cholinergic excess symptoms (headache is most common) and reduce choline supplementation if they occur.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves alpha7AChRs on interneurons in hippocampal slices from rat.
Label source:
PubMed: Kondratenko RV et al., Neurosci Lett (2022) - article title; noopept's hippocampal action involves alpha-7 nicotinic acetylcholine receptors (PMID 36195298)
Action type:
monitor
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Noopept works by enhancing the acetylcholine system, while anticholinergic medications (e.g., diphenhydramine, certain antidepressants) work by blocking it. Taking them together may reduce the effectiveness of both substances.
Actionable advice:
Co-administration with medications that have strong anticholinergic properties is best avoided, as they may counteract Noopept's benefits.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: anticholinergic agents may blunt noopept's cholinergically-mediated effects. Theoretical, minor.
Label source:
Class inference
Action type:
avoid
Target id:
/class/stimulants
Target name:
CNS Stimulants (e.g., Caffeine, Modafinil, Amphetamines)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Noopept has mild stimulant-like properties and can enhance alertness and information processing. Combining with CNS stimulants produces additive CNS activation that may cause agitation, insomnia, anxiety, or jitteriness. The monograph specifically flags the risk of sleep disturbances with this combination.
Actionable advice:
Noopept is best not combined with CNS stimulants, especially in the afternoon or evening. If combined, agitation, anxiety, and sleep disturbances should be monitored for, and a dose reduction of one or both agents considered.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Noopept is listed as a relative contraindication in pregnancy due to insufficient safety data. No teratogenicity or reproductive studies in humans have been conducted.
Actionable advice:
Noopept should not be used during pregnancy or breastfeeding due to lack of safety data.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/severe-renal-hepatic-impairment
Target name:
Severe Renal or Hepatic Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Although not formally documented, the Noopept monograph flags theoretical concerns about metabolite accumulation in patients with severe renal or hepatic impairment. Noopept is hydrolyzed by esterases to cycloprolylglycine (CPG); impaired clearance could theoretically alter its pharmacokinetic profile.
Actionable advice:
This is best used with caution in severe renal or hepatic impairment. No dose adjustment guidelines exist due to the absence of specific pharmacokinetic data in these populations.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
adjust_with_prescriber
Target id:
/condition/hypersensitivity-noopept
Target name:
Hypersensitivity to Noopept
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Hypersensitivity to noopept or related compounds is listed as an absolute contraindication.
Actionable advice:
This should not be used after a previous allergic reaction to noopept or related peptide compounds.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
General pharmacovigilance: as with any compound, prior hypersensitivity to noopept is a contraindication to re-exposure. Generic, not a specific literature finding.
Label source:
Class inference
Action type:
avoid
Target id:
/class/cholinesterase-inhibitors
Target name:
Cholinesterase Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Noopept sensitizes acetylcholine receptors while cholinesterase inhibitors (e.g., Donepezil, Huperzine A) increase acetylcholine levels. This combination can lead to an excessive cholinergic state, potentially causing severe side effects like nausea, bradycardia, and salivation.
Actionable advice:
Noopept should not be combined with any cholinesterase inhibitors unless under strict medical supervision.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves alpha7AChRs on interneurons in hippocampal slices from rat.
Label source:
PubMed: Kondratenko RV et al., Neurosci Lett (2022) - article title; noopept's hippocampal action involves alpha-7 nicotinic acetylcholine receptors (PMID 36195298)
Action type:
avoid
Target id:
/condition/hepatic-impairment
Target name:
Liver Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The metabolism and safety of Noopept have not been studied in individuals with significant liver disease. Its use is contraindicated due to unpredictable effects on drug clearance and potential for toxicity.
Actionable advice:
Noopept should not be used with a diagnosis of moderate to severe liver impairment.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/renal-impairment
Target name:
Kidney Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The clearance and safety of Noopept have not been studied in individuals with significant kidney disease. Its use is contraindicated due to unpredictable effects and potential for accumulation.
Actionable advice:
Noopept should not be used with a diagnosis of moderate to severe kidney impairment.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if Noopept or its metabolites are excreted in breast milk or what their effects on a nursing infant might be. Due to the lack of safety data, it is strictly contraindicated.
Actionable advice:
Noopept should not be used at all while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/bipolar-disorder
Target name:
Bipolar Disorder
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
By modulating key neurotransmitter systems like glutamate, Noopept could potentially destabilize mood and trigger manic or depressive episodes in individuals with bipolar disorder.
Actionable advice:
Noopept should be avoided with a history of bipolar disorder or other severe psychiatric conditions.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/dietary/meal
Target name:
Any Caloric Meal
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
2
Description:
Taking Noopept with food, particularly protein-rich meals, may reduce its absorption and bioavailability as it can compete with dietary amino acids and peptides in the gut.
Actionable advice:
Noopept is best taken on an empty stomach, at least 30 minutes before a meal or 2 hours after eating.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Noopept (NPT), a potent neuroprotective agent, suffers the problem of poor oral bioavailability (~10%)
Label source:
PubMed: Srivastava PK & Thakkar HP, Eur J Pharm Sci (2021) - noopept has low (~10%) oral bioavailability, so food/GI conditions can affect uptake (PMID 34126240)
Action type:
separate
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
6
Hours after target:
null
Description:
Due to its potential stimulating effects on neurotransmitter systems like glutamate and acetylcholine, taking Noopept late in the day may interfere with your ability to fall asleep or reduce sleep quality.
Actionable advice:
The last dose of Noopept is best taken at least 6 hours before the planned bedtime.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Class inference: as a stimulating nootropic, noopept could affect sleep if taken late; practical timing caution, not demonstrated.
Label source:
Class inference
Action type:
separate
Target id:
/dietary/alcohol-acute
Target name:
Alcohol (Acute Consumption)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Alcohol is a central nervous system depressant that can counteract the cognitive-enhancing effects of Noopept. The combined effects on the brain are unpredictable and should be avoided.
Actionable advice:
Alcohol is best avoided while using Noopept to preserve its cognitive benefits and prevent unpredictable interactions.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/hypertension
Target name:
Hypertension
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The effects of Noopept on blood pressure can be unpredictable. In individuals with pre-existing or poorly controlled hypertension, it could potentially cause elevations in blood pressure.
Actionable advice:
Noopept is best avoided with severe or uncontrolled hypertension, and it is important to consult a physician if hypertension is managed.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/choline-precursors
Target name:
Choline Precursors
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Noopept enhances the brain's use of acetylcholine. Taking a choline source (e.g., Alpha-GPC, Citicoline) provides the raw material to produce more acetylcholine, potentially enhancing effects and preventing headaches from choline depletion.
Actionable advice:
Consider taking Noopept with a choline source to support cognitive effects and reduce the risk of headaches.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: supporting cholinergic tone with a choline precursor may complement noopept's alpha-7 nicotinic mechanism. Plausible synergy, unstudied.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Noopept may have a mild blood pressure-lowering effect in some individuals. Combining it with antihypertensive medications could theoretically lead to an additive effect, increasing the risk of hypotension (low blood pressure).
Actionable advice:
If you take blood pressure medication, monitor your blood pressure when starting Noopept and consult your doctor.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor